• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 20
    • Directory
    • Solution Center
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 20
  • Directory
  • Solution Center
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Reducing the Risk of Comparator Sourcing

    Clinical Data Management

    Leveraging AI/ML Analytics for Better Clinical Development Decisions

    What is a Manufacturing Ecosystem and Why are They Growing?

    Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region

    GHO Capital, Partners Group Invest in Sterling Pharma Solutions
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    TraceLink, PharmaLink Partner to Simplify DSCSA Compliance

    "3 Key Trends" with Rafael Costa

    Schreiner MediPharm Introduces Tailored Tamper-Proof Closure Seals

    FDA Watch: Is Your Supply Chain at Risk?
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Catalent Adds New Cryogenic Capabilities at Japanese Facility

    "3 Key Trends" with Cory Lewis

    Lifecore Biomedical Enters into $150M New Financing Deal

    WuXi Biologics Receives 2023 ISPE Facility of the Year Award

    Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    FDA 2023 Inspection Roadmap: Is “Readiness” in Your Annual Objectives?

    FDA Watch: Are You Suitably Staffed?

    FDA Watch: Is Your Supply Chain at Risk?

    FDA Watch: CDER to Launch Guidance Snapshot Pilot Program

    "3 Key Trends" with Paul Josephs
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Alcami

    Societal CDMO

    CMC Pharmaceuticals

    Lannett CDMO

    Syngene International Ltd.
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Alcami

    Societal CDMO

    CMC Pharmaceuticals

    Lannett CDMO

    Syngene International Ltd.
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • White Papers
    • Podcasts
    • Infographics
    • Microsites
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    Fill-Finish in Cell & Gene Therapy

    Mitigating the inherent risks of cell and gene therapy processing with automation.

    Fill-Finish in Cell & Gene Therapy
    Allison Hoffman, Global Product Manager, Cell Therapy Technologies, Terumo BCT02.06.23
    As pharma’s therapeutic toolbox continues to evolve, cell and gene therapies (CGTs) are beginning to reach patients at commercial levels. Produced in unique settings—including small, clinical-scale manufacturing operations, dedicated facilities in hospitals, and shared clinical/processing environments—these advanced personalized therapeutics require highly integrated supply chains. These incumbent complexities can pose significant challenges in compliance with current Good Manufacturing Practices (cGMP).

    Advanced Therapies on the Horizon, Processing Innovation Required

    According to The American Society of Gene & Cell Therapy (ASGCT), there are 3,366 gene and cell therapies in development from the preclinical through pre-registration stages as of Q3 2021.1 Globally, there are 19 gene therapies (including genetically modified cell therapies), 15 RNA therapies and 54 non-genetically modified cell therapies approved to date.

    As with any rapidly growing field, there are mounting challenges for both innovators and their manufacturing partners in building out the commercial process.2,3 Expanding capacity to address increasing demand and expedite timelines can lead to bottlenecks in raw material supply and critical resources like experienced technical staff. As in the early years of monoclonal antibody development, CGTs are hampered by a lack of standardized processes.4

    Industrialization of autologous and allogeneic cell therapies is still in its infancy, and as the field matures, so must advancements to increase productivity, safety, and efficacy of treatments and reduce bottlenecks as facilities come online.

    Criticality of Fill and Finish

    CGTs require complex manufacturing and logistics choreography compared with traditional therapies, making the control of all processes paramount.

    Traditional products, both large- and small-molecule, are typically manufactured at scale with at least partly automated equipment lines. Many of these products have extensive shelf lives once manufactured and use raw materials that have similarly long expiration dates.

    CGTs require a complete reimagining of this dynamic.

    Autologous CGT therapies have patient-specific starting materials such as cell tissue, blood, bone marrow, or sometimes even a tumor sample.5 The manufacturer must then generate a therapy that is specific to the starting material. The human leukocyte antigen (HLA) typing and matching phase used to match donors and patients in allogeneic therapies has a similar circular demand chain as opposed to the linear supply chains associated with traditional pharmaceuticals.

    New requirements for effective manufacture and delivery of a CGT are now in play. Notably, the starting materials taken from patients are not as stable as synthetic materials, meaning there is a manufacturing window of days instead of years. The tissue is living, which means that there are far tighter specifications regarding temperature, time, and handling throughout processing. Cells require oxygen and nutrients when metabolically active, so these products require either just-in-time delivery to patients or cryogenic storage temperatures to preserve the cells in a metabolically inactive state.

    For providers of innovative CGTs, there is little room for anything but best-practice approaches to final product consistency.6 Considering the scalability needed to meet these advanced therapies’ commercial potential and the necessity for improving yields at increased throughput, the industry is beginning to understand it must abandon manual processes and adopt automated ones to achieve true reproducibility across operators and operations.

    Fill and finish is a very high-value step for many reasons, but two of those top the list.7 First, patient impact: CGT treatment is usually a last resort, and fill and finish is the final step before infusion. Any failure will be catastrophic because the patient will not receive the therapy. Second, economic impact: When these therapies are manufactured in GMP environments, great cost is associated with modifying cells during the Chemistry, Manufacturing and Controls (CMC) management stage. If any failure or any misstep happens now, then all money spent to that point has been wasted. Moving formulation and fill–finish from manual, open processes to closed, automated processes reduces manufacturing complexity, cost of goods (COGs), risk of contamination, and cell exposure to DMSO prior to freezing.8

    Clearly, maintaining potency and viability through fill and finish is vital. Where this step relies on manual processes, there is inherent variability, which is unsustainable in an extremely high-value manufacturing setting. The need to reduce open process steps, ensure traceability, and maintain temperature control calls for automation to help ensure consistent products and reduce risk and manufacturing costs.

    Simplifying the day-to-day operations that produce these leading-edge therapeutics is critical to the industry’s future. Advances in automation and machine control now offer new flexibility and optimized production in this exciting segment of biomanufacturing.

    Automated Fill and Finish Systems Are Key to Successful cGMP Processes

    Successful advanced cGMP processes require attention to operational details across the spectrum of therapeutic process. Every formulation or production step can present new variability and quality control challenges that require innovation, experience, and advanced systems to overcome.9

    Even experienced cGMP biomanufacturers are likely to face unique hurdles trying to ensure process robustness from the time the patient’s cells leave the clinic to when they reach the processing facility, are processed, and finally are returned to the patient. When the therapy’s delivery systems can consistently achieve verifiable reproducibility at scale, reductions to risk, labor, and other resources are sure to follow.

    Integral to the treatment path are the aseptic handling, filling, and finishing of the patient’s blood or cells. A given therapeutic process may require these fill and finish steps, or even more:

    1. Mixing: Maintain batch/cell suspension uniformity
    2. Cooling: Maintain consistent environmental temperatures  to support cell health
    3. Air removal: Remove air that can compromise the final product during cryopreservation
    4. Aliquoting: Help ensure consistency with accurate volumes
    5. Sealing: Help maintain sterility of the final product
    6. Data management: Facilitate cGMP compliance with electronic data recording and reporting

    By removing manual handling and introducing automated data management at each step, you reduce human error and other factors impacting process variability and quality. Nevertheless, there are a number of specific challenges that biopharma companies are likely to encounter and that will require advanced technical solutions to overcome. These include:

    Accurately Managing Batch-to-Batch and Process Variability

    Automating process control at each point of the therapy’s journey facilitates accuracy and quality and sets enterprise-wide process standards. Configured correctly, automated systems reduce variability in fill and finish processes by supporting:

    • Greater post-thaw viability for cell products from donors
    • Post-formulation inlet-cell viability
    • Uniformity of cell concentrations
    • Final product temperature meeting user-defined targets

    Automation also allows manufacturers to reduce the number of operators and manual processes and reduce the overall cost of goods (COGs) in production, as well as manage occupational and product quality risk.

    Setting Critical Quality Attributes Faster, More Accurately

    Automated access to data during operations enables transparent trending and tracking of the process and monitoring of key patient-centered attributes across the continuum of care. Automated data acquisition and management can help manufacturers identify critical quality attributes (CQAs) earlier and more accurately at each step in a therapeutic process.

    Defining Process Controls Early in Development

    Setting process controls early using automated data management methods is another way to leverage the technology for better scaling and compliant, accurate fill and finish operations.

    Instilling Data Management and Integrity in Operations

    Automating cell processing fill and finish is a secure path to compliance. Combined with automated, digitally controlled fill and finish processing systems, a well-engineered software application can deliver data integrity that facilitates cGMP compliance. Procedure data, for example, can be automatically transmitted between the system and the application while the system is operating. Operators can leverage common, shared software to specify processing protocols, configure materials and the device, define users, and assign permissions.

    A common digitized system provides better resource management and compliance. From tracking tubing sets and materials to capturing key compliance data electronically, a digital approach to process monitoring and control promotes cGMP for proactive regulatory compliance.

    Managing Skills, Labor Hours, and Materials with Accuracy

    For CGTs, scaling is one huge factor for therapeutic success that supports patient access to treatment. However, if scaling is to be a viable aspect of the business plan, it must be cost-efficient — production economies and pricing may depend on it.

    Automated, closed fill and finish systems reduce training time and the demands for skilled labor, because they make each point of processing more reliable and faster. That reduces error and risk, as well as improving the ability to track and trace the flow of material, timelines, and operator actions.

    Automating for Post-process Consistency and Cell Viability

    As mentioned, CGTs need to be carefully managed throughout manufacture and logistics to maintain desired temperature ranges. The most common protocol for cryostoring uses dimethyl sulfoxide (DMSO), a cryoprotectant that permeates cell membranes to reduce intracellular ice crystal formation. The trade-off is oxidative stress and gene expression changes sometimes induced by DMSO. This chemical can also damage organelles, cytoskeletons, and cell membranes, affecting cell viability and functionality. As a result, the period for which cells are exposed to DMSO needs to be carefully managed.

    In CGT processing, adding DMSO to media creates an exothermic reaction; to reduce the impact of heat generation and consistent mixing on the product, a manual system of cold packs and syringes has been used to make sure that the cells and DMSO are kept within acceptable temperature ranges.

    Air also needs to be efficiently removed from the cryopreservation bags, which must then be sealed properly to prevent embrittlement of the plastic and contamination.

    Manual documentation may be paper-based, but even if some separate electronic capture method is used, it still has to be performed by an operator. This leaves the process open to human error in the generation and recording of data which can be essential for batch release.

    So how do manufacturers mitigate these risks with automation? As with any manual process, there is a risk of operator-to-operator variability even when operators follow the same procedures. Automation ends this variability, which reduces operator-related errors and ensures workflows are managed as certified and standardized operating procedures.

    When DMSO is used, automation can help maintain cell viability by minimizing the effects of the cryoprotectant during processing by automating temperature control. It can also maintain sterility with functionally closed and disposable single-use accessories, which reduces the risk of contamination by decreasing the number of open events.

    Finally, it has a direct, positive effect on reproducibility, consistency, and assurance that manufacturers have the right target volumes in the product bags with consistent concentration of cells.

    Summary

    Adopting automation technologies into fill and finish processing presents many benefits, including consistency, repeatability, sterility assurance, and reduced human error.

    These qualities are essential in CGT to deliver a cGMP process that successfully delivers a product for its intended patient.

    Ultimately, more robust and efficient fill and finish lines de-risk development and manufacturing for very high-value products. 

    References

    1. “ASGCT, Informa Pharma Intelligence. Gene, Cell, & RNA Therapy Landscape. Q3 2021 Quarterly Report.  Accessed February 21, 2022.” https://asgct.org/global/documents/asgct-pharma-intelligence-quarterly-report-q3-2021.aspx
    2. “The Regulatory Framework for CAR-T Cells in Europe: Current Status and Foreseeable Changes AND Centre Qualification by Competent Authorities and Manufacturers.” 10.1016/j.biotechadv.2021.107735
    3. “Automation, Monitoring, and Standardization of Cell Product Manufacturing.” 10.3389/fbioe.2020.00811
    4. “Standardization, workforce development and advocacy in cell and gene therapies: a summary of the 2020 Regenerative Medicine InterCHANGE.” 10.1016/j.jcyt.2021.02.004
    5. “International alliance and AGREE-ment of 71 clinical practice guidelines on the management of critical care patients with COVID-19: a living systematic review.” 0.1016/j.xphs.2020.07.002
    6. “Objectives, benefits and challenges of bioreactor systems for the clinical-scale expansion of T lymphocyte cells.”10.1016/j.biotechadv.2021.107735.” 10.1007/978-3-030-94353-0_37
    7. “Regulatory Landscape and Emerging Trends in Advanced Therapy Manufacturing: An EU Perspective.” 10.1007/978-3-030-75537-9_2
    8. “Formulation Considerations for Autologous T Cell Drug Products.” 10.3390/pharmaceutics13081317
    9. “Automation in cell and gene therapy manufacturing: from past to future.” 10.1007/s10529-019-02732-z

    Allison Hoffman is Global Product Manager of Cell Therapy Technologies at Terumo Blood and Cell Technologies.
    Related Searches
    • Biologics, Proteins, Vaccines
      Loading, Please Wait..
      Trending
      • Aurigene Expands Biologics CDMO Capacity
      • Contract Pharma
      • Catalent Adds New Cryogenic Capabilities At Japanese Facility
      • Societal CDMO Partners With Atossa Therapeutics
      • Videobite: Contract Pharma Sits Down with Ryan Lake of Societal CDMO
      Breaking News
      • Catalent Adds New Cryogenic Capabilities at Japanese Facility
      • Lifecore Biomedical Enters into $150M New Financing Deal
      • WuXi Biologics Receives 2023 ISPE Facility of the Year Award
      • Thermo Fisher Expands Steriles Facility in Asia-Pacific Region
      • GHO Capital, Partners Group Invest in Sterling Pharma Solutions
      View Breaking News >
      CURRENT ISSUE

      May 2023

      • New Modalities Hog the Limelight
      • Cell and Gene Therapy is Coming of Age
      • Demand Surges for Cell and Gene Therapy Contract Manufacturing
      • Embracing a New Reality
      • Japan: A Unique Opportunity for Regenerative Medicines and Cell & Gene Therapies
      • Single-Use Technologies Enable Biologic Scaling
      • Get Smart: Integrating PAT Data into Existing Biotech Data Infrastructures
      • FTEs in Drug Discovery
      • Digital Transformation in Pharma
      • What is a Manufacturing Ecosystem and Why are They Growing?
      • View More >

      Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
      You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

      • About Us
      • Privacy Policy
      • Terms And Conditions
      • Contact Us

      follow us

      Subscribe
      Nutraceuticals World

      Latest Breaking News From Nutraceuticals World

      Premium Label & Packaging Solutions Receives Safe Quality Food (SQF) Certification
      Inulinase Enzymes May Benefit Gut Symptoms of FODMAP Digestion
      Verdure Sciences’ Boswellia Ingredient Receives USP Verification
      Coatings World

      Latest Breaking News From Coatings World

      OQ Chemicals Launches Cost-Cutting Program and Organizational Realignment in Germany
      BASF Strengthens R&D with More Powerful Supercomputer
      Safic-Alcan Expands its Presence in Africa with the Launch of Safic-Alcan East Africa in Kenya
      Medical Product Outsourcing

      Latest Breaking News From Medical Product Outsourcing

      Vascular Surgeon Imprisoned and Fined for Decade-Long Healthcare Fraud
      Remote Monitoring, Digital Health Help Advance Wound Care Treatment
      MLM Biologics Developing Wound Infection Prevention Device for Military
      Contract Pharma

      Latest Breaking News From Contract Pharma

      Catalent Adds New Cryogenic Capabilities at Japanese Facility
      Lifecore Biomedical Enters into $150M New Financing Deal
      WuXi Biologics Receives 2023 ISPE Facility of the Year Award
      Beauty Packaging

      Latest Breaking News From Beauty Packaging

      How Robots & Artificial Intelligence are Transforming Unilever's Material Innovation Factory
      Top 10 Most Popular Hair Care Brands in the U.S.—Ranked by Searches
      Aloette Cosmetics Launches Daily Mineral Shield Sunscreen
      Happi

      Latest Breaking News From Happi

      Revieve Launches Beauty Technology Platform on Google Cloud Marketplace
      BBW’s Fabric Softener Launch, Ameon’s New Ambassador
      Mielle Organics Taps Angel Reese as New Ambassador
      Ink World

      Latest Breaking News From Ink World

      Weekly Recap: INX Digital, Mexar and hubergroup Top This Week’s Stories
      Richnerstutz AG Acquires an EFI VUTEk Q5r Superwide Roll-to-Roll Printer
      BASF Strengthens Its R&D with More Powerful Supercomputer
      Label & Narrow Web

      Latest Breaking News From Label & Narrow Web

      Mactac acquires Label Supply, Beontag grows and more
      Sun Chemical releases Spring 2023 Regulatory Newsletter
      Tageos unveils new RAIN RFID inlays
      Nonwovens Industry

      Latest Breaking News From Nonwovens Industry

      Weekly Recap: Corman, Tosama Develop Biodegradable Plastic Tampon Applicator, Trevira Changes Name
      Suominen Appoints SVP, Transformation Management Office
      Minnesota Signs PFAS Ban in Consumer Products
      Orthopedic Design & Technology

      Latest Breaking News From Orthopedic Design & Technology

      AlloSource Launches AlloMend Duo Acellular Dermal Matrix
      TendoNova Inks Partnership With AcCELLerated Biologics
      Stryker Achieves First Surgeries Using Q Guidance System with Cranial Guidance Software
      Printed Electronics Now

      Latest Breaking News From Printed Electronics Now

      Weekly Recap: Smart Skis, Universal Display Top This Week’s Stories
      Wiliot Appoints Antony Yousefian as VP of Climate & Circularity
      HID Unveils Eco-friendly Bamboo Access Cards

      Copyright © 2023 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

      AD BLOCKER DETECTED

      Our website is made possible by displaying online advertisements to our visitors.
      Please consider supporting us by disabling your ad blocker.


      FREE SUBSCRIPTION Already a subscriber? Login